Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial J Am Coll Cardiol. 2015;66(21): doi: /j.jacc Figure Legend: Kaplan-Meier Curve of Time to First Major GI Bleeding Event by Treatment Arm Rivaroxaban-treated patients had a significantly shorter time to their first major gastrointestinal (GI) bleeding event compared with warfarin- treated patients during follow-up in the ROCKET AF trial.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial J Am Coll Cardiol. 2015;66(21): doi: /j.jacc Figure Legend: GI Bleeding in ROCKET AF Trial: Histogram of the Distribution of GI Bleeding Stratified by Treatment Arm Rivaroxaban-treated patients had higher rates of major and minor gastrointestinal (GI) bleeding events compared with warfarin-treated patients; however, rates of the most severe GI bleeding events, including those that required transfusion of packed red blood cells and those that resulted in death, were comparable between treatment groups.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial J Am Coll Cardiol. 2015;66(21): doi: /j.jacc Figure Legend: Predicted 1-Year Event Rate (With Point-Wise 95% CI) for the “Average” Patient On multivariable modeling, predicted 1-year GI bleeding event rates were lowest for patients with average international normalized ratio (INR) values of 2.0, with incremental increased risk for each INR unit above and below 2.0. Average values for all other covariates shown for the range of 1st to 99th percentiles of INR distribution. CI = confidence interval; GI = gastrointestinal.